Genmab (Nasdaq: GMAB) director sells 526 shares on NASDAQ Copenhagen
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Genmab A/S filed a Form 6-K reporting insider trading activity by a managerial employee. Board member Michael Kavanagh sold 526 Genmab shares on May 29, 2026 on NASDAQ Copenhagen at a price of DKK 1,734.75 per share.
The filing is made under European Market Abuse Regulation Article 19 and is incorporated by reference into several of Genmab’s employee share plan registration statements on Form S-8. Genmab also reiterates its focus on antibody-based medicines and includes standard forward-looking statement risk disclosures.
Positive
- None.
Negative
- None.
Key Figures
Shares sold: 526 shares
Share price: DKK 1,734.75 per share
Transaction date: 2026-05-29
+2 more
5 metrics
Shares sold
526 shares
Aggregated transaction volume by director Michael Kavanagh
Share price
DKK 1,734.75 per share
Price for each Genmab A/S share sold on May 29, 2026
Transaction date
2026-05-29
Date of director share sale on NASDAQ Copenhagen
Instrument identification
DK0010272202
ISIN of Genmab A/S shares traded
LEI code
529900MTJPDPE4MHJ122
Legal Entity Identifier for Genmab A/S
Key Terms
Market Abuse, Regulation No. 596/2014, Implementing Regulation 2016/523, LEI-code, +1 more
5 terms
Market Abuse regulatory
"In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse"
Market abuse is illegal or unethical behavior that distorts the price or fairness of buying and selling financial assets, such as using secret information to trade, spreading false or misleading news, or creating fake buying and selling to give a false impression of demand. It matters to investors because it can cause unfair losses, unreliable prices and legal or reputational fallout; like cheating in a game or tampering with a scale, it destroys confidence that markets reflect true value.
Regulation No. 596/2014 regulatory
"In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse"
A European law that sets rules to prevent insider trading, market manipulation and misleading disclosures in financial markets, requiring companies and market participants to share important information publicly and handle inside information carefully. It matters to investors because it aims to keep markets fair and transparent—like traffic rules that reduce crashes—so prices reflect real facts and not hidden advantages, helping protect investor trust and reduce the risk of unexpected losses.
Implementing Regulation 2016/523 regulatory
"and Implementing Regulation 2016/523, this document discloses the data of the transactions"
LEI-code financial
"b) | LEI-code | 529900MTJPDPE4MHJ122"
forward looking statements regulatory
"The Company Announcement contains forward looking statements."
Statements about a company’s expected future performance, plans, goals, or projections that are not historical facts and involve assumptions and estimates. Investors care because these are predictions that guide decisions but can be wrong; like a weather forecast, they help set expectations and risk — if circumstances change, actual results may differ significantly, so investors should weigh them alongside hard data and risk factors.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF MAY 2026
COMMISSION FILE NUMBER 001-38976
Genmab A/S
(Exact name of Registrant as specified in its charter)
(Exact name of Registrant as specified in its charter)
Carl Jacobsens Vej 30
2500 Valby
Denmark
+45 70 20 27 28
(Address of principal executive offices)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit | Description of Exhibit | ||||
| 99.1 | Company Announcement Dated May 29, 2026: Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENMAB A/S | ||||||||
| BY: | /s/ Anthony Pagano | |||||||
| Name: Anthony Pagano | ||||||||
| Title: Executive Vice President & Chief Financial Officer | ||||||||
DATE: MAY 29, 2026
Exhibit 99.1
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Company Announcement
COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.
Please find below a statement of such trading in shares issued by Genmab A/S.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | ||||||||||
| a) | Name | Michael Kavanagh | |||||||||
| 2. | Reason for the notification | ||||||||||
| a) | Position/status | Member of the Board of Directors | |||||||||
| b) | Initial notification/Amendment | Initial notification | |||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||
| a) | Name | Genmab A/S | |||||||||
| b) | LEI-code | 529900MTJPDPE4MHJ122 | |||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||
| a) | Description of the financial instrument, type of instrument Identification code | Share DK0010272202 | |||||||||
| b) | Nature of the transaction | Sale of shares | |||||||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||||||||
| DKK1,734.75 | 221 | ||||||||||
| DKK1,734.75 | 305 | ||||||||||
| d) | Aggregated information - Aggregated volume - Price | 526 shares DKK 1,734.75 | |||||||||
| e) | Date of the transaction | 2026-05-29 | |||||||||
| f) | Place of the transaction | NASDAQ Copenhagen (XCSE) | |||||||||
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 28 Page 1/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 28 Page 2/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
FAQ
What insider transaction did Genmab (GMAB) disclose in this Form 6-K?
Genmab disclosed that board member Michael Kavanagh sold 526 Genmab A/S shares on May 29, 2026 on NASDAQ Copenhagen. The shares were sold at a price of DKK 1,734.75 each, under European Market Abuse Regulation reporting rules.
Who is the Genmab (GMAB) insider involved and what is his role?
The insider is Michael Kavanagh, a Member of the Board of Directors of Genmab A/S. His share sale was disclosed as a managerial employee transaction under Article 19 of Market Abuse Regulation, requiring public reporting of trades in Genmab shares.
Why is Genmab (GMAB) publishing this insider trading information?
Genmab publishes this information to comply with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523. Managerial employees and closely associated persons gave Genmab power of attorney to disclose their trading in Genmab A/S shares.
What business focus does Genmab (GMAB) highlight in this announcement?
Genmab highlights its role as an international biotechnology company focused on innovative antibody medicines, including bispecific antibodies and ADCs. It notes that its science powers eight approved antibody medicines and a strong late-stage clinical pipeline targeting cancer and other serious diseases.